Natera, Inc. (NASDAQ:NTRA) Stock Holdings Lifted by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its position in Natera, Inc. (NASDAQ:NTRA) by 25.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,229,558 shares of the medical research company’s stock after purchasing an additional 246,246 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.99% of Natera worth $156,092,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Itau Unibanco Holding S.A. bought a new stake in shares of Natera during the 2nd quarter worth about $28,000. Quarry LP boosted its stake in shares of Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares in the last quarter. Tobam bought a new stake in shares of Natera during the 2nd quarter worth about $74,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of Natera during the 1st quarter worth about $83,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on NTRA. The Goldman Sachs Group upped their price target on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday. Canaccord Genuity Group increased their target price on Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th. TD Cowen increased their target price on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. UBS Group decreased their target price on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Finally, Robert W. Baird increased their target price on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $124.44.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 2,638 shares of Natera stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $105.16, for a total value of $277,412.08. Following the completion of the transaction, the chief executive officer now owns 210,377 shares in the company, valued at approximately $22,123,245.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Solomon Moshkevich sold 549 shares of Natera stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $105.16, for a total value of $57,732.84. Following the completion of the sale, the insider now directly owns 113,637 shares of the company’s stock, valued at approximately $11,950,066.92. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 2,638 shares of Natera stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $105.16, for a total value of $277,412.08. Following the completion of the sale, the chief executive officer now directly owns 210,377 shares of the company’s stock, valued at $22,123,245.32. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,765 shares of company stock worth $6,016,700. 7.60% of the stock is currently owned by insiders.

Natera Price Performance

Shares of Natera stock traded up $0.05 during midday trading on Friday, hitting $122.40. 985,355 shares of the company were exchanged, compared to its average volume of 1,085,650. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The firm has a market cap of $15.03 billion, a P/E ratio of -39.23 and a beta of 1.53. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $133.54. The firm has a 50 day simple moving average of $123.30 and a 200-day simple moving average of $110.49.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. During the same quarter in the previous year, the company posted ($0.97) EPS. The business’s revenue for the quarter was up 58.1% compared to the same quarter last year. Research analysts forecast that Natera, Inc. will post -1.96 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.